Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy

Diabetic Medicine

Volumn 27, Issue 10, 2010, Pages 1178-1187

  Victoria, B ^a   Cabezas Agricola J M ^b   Gonzalez Mendez B ^a   Lattanzi, G ^c   Del Coco, R ^c   Loidi, L ^b   Barreiro, F ^a   Calvo, C ^b   Lado Abeal, J ^a,d   Araujo Vilar D ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c CNR   (Italy)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Beradinelli Seip syndrome; fibroblast; gene expression; glitazone; seipin

Indexed keywords

ENALAPRIL; FENOFIBRATE; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PROTEIN PRELAMIN A; PROTEIN SEIPIN; ROSIGLITAZONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADOLESCENT; ANTHROPOMETRY; ARTICLE; CASE REPORT; CELL CULTURE; CELL DIFFERENTIATION; CONGENITAL GENERALIZED LIPODYSTROPHY; CULTURE MEDIUM; DRUG DOSE INCREASE; EXERCISE; FAT BODY; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LABORATORY TEST; LIPID ANALYSIS; MALE; MENTAL DEFICIENCY; METABOLIC RATE; PHYSICAL EXAMINATION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; WESTERN BLOTTING;

ADIPOGENESIS; ADOLESCENT; BLOTTING, WESTERN; FIBROBLASTS; GENE EXPRESSION; HUMANS; LIPODYSTROPHY, CONGENITAL GENERALIZED; MALE; THIAZOLIDINEDIONES;

EID: 77956846954     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03052.x     Document Type: Article

References (49)

1. Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O'Rahilly S et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 2003 88 : 4840 4847.
2. Seip M, Trygstad O. General lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr 1996 413 (Suppl 2 28.
3. Sovik O, Vestergaard H, Trygstad O, Pedersen O. Studies of insulin resistance in congenital generalized lipodystrophy. Acta Paediatr 1996 413 (Suppl 29 37.
4. Fu M, Kazlauskaite R, Baracho Mde F, Santos MG, Brandão-Neto J, Villares S et al. Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects. J Clin Endocrinol Metab 2004 89 : 2916 2922.
5. Pardini VC, Victoria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB et al. Leptin levels, β-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998 83 : 503 508.
6. Van Maldergem L, Magre J, Khallouf TE, Gedde-Dahl T Jr., Delépine M, Trygstad O et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet 2002 39 : 722 733.
7. Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F et al. A gene for congenital lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999 84 : 3390 3394.
8. Agarwal A, Arioglu E, Almeida S, Akkoc N, Taylor SI, Bowcock AM et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002 31 : 21 23.
9. Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr., Van Maldergem L, Sobel E et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001 28 : 365 370.
10. Kim C, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip Congenital Lipodystrophy. J Clin Endocrinol Metab 2008 93 : 1129 1134.
11. Lundin C, Nordstrom R, Wagner K, Windpassinger C, Andersson H, von Heijne G et al. Membrane topology of the human seipin protein. FEBS Letters 2006 580 : 2281 2284.
12. Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, Hörl G et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 2004 36 : 271 276. (Pubitemid 38282752)
13. Payne VA, Grimsey N, Tuthill A, Virtue S, Gray SL, Dalla Nora E et al. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes 2008 57 : 2055 2060.
14. Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK et al. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A 2007 104 : 20890 20895.
15. Boutet E, El Mourabit H, Prot M, Nemani M, Khallouf E, Colard O et al. Seipin deficiency alters fatty acid Δ9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie 2009 91 : 796 803.
16. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 2006 86 : 967 1008.
17. Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet 2005 14 : 1489 1502.
18. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996 87 : 377 389.
19. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998 338 : 861 866.
20. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994 79 : 1147 1156.
21. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy. A randomized, controlled trial. Ann Intern Med 2004 140 : 786 794.
22. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000 133 : 263 274.
23. Owen KR, Donohoe M, Ellard S, Hattersley AT. Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 2003 20 : 823 827.
24. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 2003 52 : 910 917.
25. Araújo-Vilar D, Sarmiento LM, Barros N, Costa da Silva Freitas AT, Ramazanova A, Lado-Abeal J et al. Resting metabolic rate is reduced in some obese subjects' subpopulations. Obes Metab 2008 4 : 22 27.
26. Araújo-Vilar D, Garcia-Estevez DA, Cabezas-Cerrato J. Both a reduced acute insulin response to glucose and lower glucose effectiveness are responsible for the worsening of intravenous glucose tolerance in healthy subjects independently of the degree of obesity. Metabolism 1998 47 : 313 320.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual, 2nd edn. New York : Cold Spring Harbor Laboratory Press, 1989.
28. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990 51 : 1106 1112.
29. Frayn KN. Indirect calorimetry. Metabolism 1988 37 : 1185 1192.
30. Araújo-Vilar D, Rega-Liste CA, Garcia-Estevez DA, Sarmiento-Escalona F, Mosquera-Tallon V, Cabezas-Cerrato J. Minimal model of glucose metabolism: modified equations and its application in the study of insulin sensitivity in obese subjects. Diabetes Res Clin Pract 1998 39 : 129 141.
31. Parpal S, Karlsson M, Thorn H, Stralfors P. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate but not for mitogen-activated protein kinase control. J Biol Chem 2001 276 : 9670 9678.
32. -CT method. Methods 2001 25 : 402 408.
33. Dominici S, Fiori V, Magnani M, Schena E, Capanni C, Camozzi D et al. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria. Eur J Histochem 2009 53 : 43 52.
34. Araújo-Vilar D, Loidi L, Domínguez F, Cabezas-Cerrato J. Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482W mutation. Horm Metab Res 2003 35 : 29 35.
35. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004 350 : 1220 1234.
36. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients Diabetes Care 2006 29 : 554 559.
37. Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006 8 : 197 205.
38. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000 49 : 782 788.
39. Gambineri A, Semple RK, Forlani G, Genghini S, Grassi I, Hyden CS et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol 2008 159 : 347 353.
40. Lüdtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 2005 22 : 1611 1613.
41. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003 8 : 199 207.
42. Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab 2007 33 : 385 389.
43. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, Ralph A et al. Thiazolidinediones improve β-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab 2007 292 : E871 E883.
44. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 26 : 744 754.
45. Fischer P, Möller P, Bindl L, Melzner I, Tornqvist H, Debatin KM et al. Induction of adipocyte differentiation by a thiazolidinedione in cultured, subepidermal, fibroblast-like cells of an infant with congenital generalized lipodystrophy. J Clin Endocrinol Metab 2002 87 : 2384 2390.
46. Chen W, Yechoor VK, Chang BHJ, Li MV, March KL, Chan L. The Human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology 2009 150 : 4552 4561.
47. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006 44 : 1191 1205.
48. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004 110 : 1492 1498.
49. Boguslavsky RL, Colin L, Stewart CL, Worman HJ. Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2006 15 : 653 663.